Senores Pharmaceuticals Limited has issued a corporate guarantee of USD 1,500,000 to secure additional credit facilities for its US-based material subsidiary. The pharmaceutical company informed stock exchanges about this financial commitment on March 03, 2026, pursuant to regulatory disclosure requirements.

Corporate Guarantee Details

The company has provided the guarantee to HDFC Bank Limited for credit facilities availed by Havix Group Inc. D/B/A Aavis Pharmaceuticals, its material subsidiary based in the USA. This follows an earlier intimation dated July 10, 2025, indicating ongoing financial support for the subsidiary's operations.

Terms and Conditions

The corporate guarantee remains valid until the closure of the credit facilities or their tenure, whichever occurs earlier. The maximum tenure for these credit facilities is set at 10 years, providing long-term financial flexibility for the subsidiary's operations.

The guarantee is structured to secure additional credit facilities, suggesting expansion or enhanced working capital requirements for the US subsidiary's pharmaceutical operations.

Regulatory Compliance and Disclosures

Senores Pharmaceuticals disclosed this transaction under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that promoters and promoter groups have interest in this transaction through their directorship in the material subsidiary, though the guarantee is extended at arm's length.

Financial Impact Assessment

At present, the corporate guarantee has no direct impact on Senores Pharmaceuticals Limited other than its disclosure as a contingent liability in the company's financial statements. This indicates that the subsidiary's credit facilities are performing as expected, with no immediate call on the guarantee anticipated.

The guarantee demonstrates the parent company's confidence in its US subsidiary's business prospects and its commitment to supporting international operations through strategic financial backing.

Senores Pharmaceuticals Limited has disclosed the creation of a pledge by its promoter group entity Espee Therapeutics LLP on 4,00,000 equity shares. The pledge was created under the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, and reported to both BSE and NSE on February 17, 2026.

Pledge Details

The pledge creation involves specific financial and operational parameters that demonstrate the structured nature of the transaction.

Promoter Group Holdings

Espee Therapeutics LLP holds a total of 4,95,000 equity shares in Senores Pharmaceuticals Limited, representing 1.0748% of the company's total share capital. The pledged shares constitute a significant portion of the entity's total holding in the company.

Regulatory Compliance

The disclosure was made pursuant to Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company secretary Vinay Kumar Mishra (ICSI Membership No.: F11464) submitted the disclosure on behalf of Senores Pharmaceuticals Limited, while Swapnil Jatinbhai Shah, Designated Partner (DIN: 05259821), signed the disclosure on behalf of Espee Therapeutics LLP.

Stock Exchange Listing

Senores Pharmaceuticals Limited is listed on both major Indian stock exchanges with the following identifiers:

• BSE Scrip Code: 544319
• NSE Symbol: SENORES

The disclosure ensures transparency and compliance with regulatory requirements for substantial shareholding changes and encumbrance creation by promoter group entities.